FDA approves lixisenatide as AdlyxinTM for the treatment of adults with type 2 diabetes in the U.S.

FDA approves lixisenatide as AdlyxinTM for the treatment of adults with type 2 diabetes in the U.S.

This post was originally published on this site

FDA is currently reviewing iGlarLixi, the fixed-ratio combination of AdlyxinTM and LantusA , with regulatory decision expected in August 2016 Zealand is eligible to receive remaining milestone payments of up to $135 million as well as royalties on global sales Zealand Pharma , a biotechnology company, announces that the U.S. Food and Drug Administration has granted approval of lixisenatide for the treatment of adults with type 2 diabetes. Lixisenatide, a once-daily prandial GLP-1 receptor agonist, was indicated as an adjunct to diet and exercise for the treatment of adults with type 2 diabetes, including in combination with oral anti-diabetes medication and/or basal insulin.

Start the conversation, or Read more at GlobeNewswire.